Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Adoptive CD4+ T-Cell Transfer for Cancer Immunotherapy
EF 2009-10
Résumé
Cancer is currently a leading cause of death throughout many parts of the world. Despite great advancement in the treatment of primary tumors through the use of radiation, chemotherapies and targeted therapies, disseminated cancers continue to present a significant problem as conventional therapies are poorly effective against metastases. One particularly promising area of therapeutic development is immunotherapy, which employs the patient's own immune system to attack cancer cells. This is of particular interest for metastatic cancers, as immune cells are able to circulate throughout the body and locate and clear these metastases. Since tumors arise from normal tissues, there are concerns that successful development of immunity against a tumor will also result in destruction of healthy tissues. Our research has demonstrated that it is possible to produce robust immunity against the tumor while leaving healthy tissues undamaged.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
206232
Name
Vanseggelen Heather
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Adoptive CD4+ T-Cell Transfer for Cancer Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Transfer; Autoimmunity; Cancer Therapeutics; Cancer Vaccines; Gene Therapy; T-Cells; Tumor Immunity; Viral Vectors
Abstract
Cancer is currently a leading cause of death throughout many parts of the world. Despite great advancement in the treatment of primary tumors through the use of radiation, chemotherapies and targeted therapies, disseminated cancers continue to present a significant problem as conventional therapies are poorly effective against metastases. One particularly promising area of therapeutic development is immunotherapy, which employs the patient's own immune system to attack cancer cells. This is of particular interest for metastatic cancers, as immune cells are able to circulate throughout the body and locate and clear these metastases. Since tumors arise from normal tissues, there are concerns that successful development of immunity against a tumor will also result in destruction of healthy tissues. Our research has demonstrated that it is possible to produce robust immunity against the tumor while leaving healthy tissues undamaged.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Vanseggelen, Heather
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~